Proteus
Report Name: 2003 Pedi Proteus mirabilis
Query Selection Criteria:
Report Start Date: 01/01/2003 (MM/DD/YYYY)
Report End Date: 12/31/2003 (MM/DD/YYYY)
Organism: Proteus mirabilis
Drug: Amikacin;Ampicillin;Cefazolin;Cefepime;Cefotaxime;Ceftazidime;Ce
ftriaxone;Ciprofloxacin;Colistin;Gentamicin;Imipenem;Nitrofurantoi
n;Piperacillin;Piperacillin/tazobactam;Tobramycin;Trimeth/sulfa
Breakpoint: NCCLS
Patient Type: Inpatient;Inpatient - ICU;Outpatient
Patient Age: greater than or equal to 0 AND less than or equal to 18
Institution: T84 University of CA at San Francisco - Parnassus
Street-ALL;T84 Mt. Zion Medical Center - Divisedero Street
Trending: None
Dataset: Institution
Chosen Country: United States
Organism Proteus mirabilis S S I I R R
Drug Total N % N % N %
Amikacin 21 21 100.0 % 0 0.0 % 0 0.0 %
Ampicillin 21 17 81.0 % 0 0.0 % 4 19.0 %
Cefazolin 21 21 100.0 % 0 0.0 % 0 0.0 %
Cefepime 21 21 100.0 % 0 0.0 % 0 0.0 %
Cefotaxime 21 21 100.0 % 0 0.0 % 0 0.0 %
Ceftazidime 21 21 100.0 % 0 0.0 % 0 0.0 %
Ceftriaxone 21 21 100.0 % 0 0.0 % 0 0.0 %
Ciprofloxacin 21 20 95.2 % 0 0.0 % 1 4.8 %
Gentamicin 21 17 81.0 % 0 0.0 % 4 19.0 %
Imipenem 21 21 100.0 % 0 0.0 % 0 0.0 %
Nitrofurantoin 18 0 0.0 % 1 5.6 % 17 94.4 %
Piperacillin 4 3 75.0 % 0 0.0 % 1 25.0 %
Piperacillin/tazobactam 21 21 100.0 % 0 0.0 % 0 0.0 %
Tobramycin 21 17 81.0 % 1 4.8 % 3 14.3 %
Trimeth/sulfa 21 17 81.0 % 0 0.0 % 4 19.0 %
For agents with >25% of strains tested:
Plain=<60% activity